OncRef

Clinical Trial: NCT04195750

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Merck Sharp & Dohme LLC
Information Provided By:Merck Sharp & Dohme LLC
Last Update Posted:2026-10-20

Study Overview

Brief Summary

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.

Official Title

An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

Conditions

Carcinoma, Renal Cell

Intervention / Treatment

  • Drug: Belzutifan
  • Drug: Everolimus

Other Study ID Numbers

  • 6482-005
  • MK-6482
  • 205262
  • jRCT2080225166
  • 2023-506635-15-00
  • U1111-1294-1321
  • 2019-003444-72
  • 2019
  • 2023

Start Date (Actual)

2020-02-27

Primary Completion Date (Actual)

2024-04-15

Study Completion Date (Estimated)

2026-10-14

Enrollment (Actual)

755

Study Type

Interventional

Phase

Phase 3